ArticleOncotarget2016
Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Influence of Nutrition in Alzheimer's Disease: Neuroinflammation and the Microbiome vs. Transmissible Prion.Frontiers in neuroscience · 2021Pooled it
- Ideal animal models according to multifaceted mechanisms and peculiarities in neurological disorders: present and challenges.Archives of pharmacal research · 2025Review
- Melatonin Overexpression in the Management of Alzheimer's Disease: Therapeutic Exploration.Current topics in medicinal chemistry · 2025Review
- Review
- Review
- Sensor-integrated brain-on-a-chip platforms: Improving the predictive validity in neurodegenerative research.Bioengineering & translational medicine · 2024Review
- Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History.Journal of clinical medicine · 2024Review
- G × E interactions as a basis for toxicological uncertainty.Archives of toxicology · 2023Article
- Brain organoids and organoid intelligence from ethical, legal, and social points of view.Frontiers in artificial intelligence · 2023Review
- EMF Antenna Exposure on a Multilayer Human Head Simulation for Alzheimer Disease Treatments.Journal of biomedical science and engineering · 2022Article
- Worldwide impact of lifestyle predictors of dementia prevalence: An eXplainable Artificial Intelligence analysis.Frontiers in big data · 2022Article
- A Novel Explainability Approach for Technology-Driven Translational Research on Brain Aging.Journal of Alzheimer's disease : JAD · 2022Review
- Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer's patients.Cell stem cell · 2021Article
- Gene-Environment Interactions in Developmental Neurotoxicity: a Case Study of Synergy between Chlorpyrifos and CHD8 Knockout in Human BrainSpheres.Environmental health perspectives · 2021Article
- Homocysteine fibrillar assemblies display cross-talk with Alzheimer's disease β-amyloid polypeptide.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Alzheimer's Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research.Animals : an open access journal from MDPI · 2020Review
- A Brainer on Neurotoxicity.Frontiers in toxicology · 2020Article
- Non-Aβ-Dependent Factors Associated with Global Cognitive and Physical Function in Alzheimer's Disease: A Pilot Multivariate Analysis.Journal of clinical medicine · 2019Article
- Brain-Gut-Microbiota Axis in Alzheimer's Disease.Journal of neurogastroenterology and motility · 2019Review
- Menagerie: A text-mining tool to support animal-human translation in neurodegeneration research.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Much of Alzheimer disease (AD) research has been traditionally based on the use of animals, which have been extensively applied in an effort to both improve our understanding of the pathophysiological mechanisms of the disease and to test novel therapeutic approaches. However, decades of such research have not effectively translated into substantial therapeutic success for human patients. Here we critically discuss these issues in order to determine how existing human-based methods can be applied to study AD pathology and develop novel therapeutics. These methods, which include patient-derived cells, computational analysis and models, together with large-scale epidemiological studies represent novel and exciting tools to enhance and forward AD research. In particular, these methods are helping advance AD research by contributing multifactorial and multidimensional perspectives, especially considering the crucial role played by lifestyle risk factors in the determination of AD risk. In addition to research techniques, we also consider related pitfalls and flaws in the current research funding system. Conversely, we identify encouraging new trends in research and government policy. In light of these new research directions, we provide recommendations regarding prioritization of research funding. The goal of this document is to stimulate scientific and public discussion on the need to explore new avenues in AD research, considering outcome and ethics as core principles to reliably judge traditional research efforts and eventually undertake new research strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.